Trial Profile
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 29 Sep 2021 Status changed from active, no longer recruiting to completed.
- 17 Sep 2021 Planned End Date changed from 12 Jan 2023 to 23 Sep 2021.
- 17 Sep 2021 Planned primary completion date changed from 12 Jan 2023 to 23 Sep 2021.